J

Johnson & Johnson

Makes prescription drugs and medical devices

Experienced Specialist, Quality Assurance

Full-TimeUpdated on 10/15/2026Deadline 10/16/26
€53.5k - €85.4k+ Annual bonus
Senior
Bachelor's, Master's
Sassenheim, Netherlands
Hybrid
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A Bachelor's degree or higher in Biochemistry, Biology, Pharmaceutical Sciences, or another relevant scientific field.
  • At least 6 years of experience in a GMP-regulated environment with a Bachelor's degree, or 4 years with a Master's degree.
  • Experience within Quality Assurance, Quality Control, manufacturing operations, or related pharmaceutical or biotechnology environments.
  • Proven knowledge of the biotechnology and/or pharmaceutical industry.
  • Strong understanding of global regulatory requirements, including current good manufacturing practice (cGMP), International Council for Harmonisation (ICH), U.S. Food and Drug Administration (FDA), and European Medicines Agency (EMA) expectations.
  • Knowledge of Quality Systems, including change control, deviation management, Corrective and Preventive Actions (CAPA), validation, and risk management.
  • Understanding of manufacturing processes, laboratory operations, facilities, utilities, and technical automation systems.
  • Experience supporting investigations, troubleshooting activities, and development of compliant solutions to quality issues.
  • Ability to work independently and make risk-based decisions in a complex environment.
  • Strong analytical, problem-solving, and decision-making skills.
  • Ability to balance business needs, regulatory requirements, quality expectations, and patient impact.
  • Strong collaboration, influencing, and negotiation skills.
  • Ability to engage partners and navigate differing viewpoints effectively.
  • Strong written and verbal communication skills.
  • Fluency in English.
  • Understanding of artificial intelligence (AI) concepts and frameworks, including awareness of responsible and ethical AI practices, and use of effective prompting techniques to support efficiency and productivity.
Responsibilities
  • Provide Quality Assurance oversight for Advanced Therapies manufacturing operations and help ensure products, processes, equipment, and systems operate in accordance with GMP requirements and regulatory expectations.
  • Assess investigations, participate in risk management activities, provide quality guidance on manufacturing and support processes, and help maintain inspection readiness across the site.
  • Provide oversight for Advanced Therapies production activities at the site.
  • Provide quality guidance for GMP processes, including Change Control, Document Control, GMP Training, and inspection readiness.
  • Provide quality guidance for facility, utility, and equipment design activities, including new facility projects.
  • Support technology transfers, analytical transfers, qualification programs, and validation activities.
  • Support aseptic processing operations and Annex 1 compliance requirements.
  • Review and assess Quality Investigations and monitor the quality of root cause investigations.
  • Assess non-conformances for potential impact on product quality or compliance status and support product disposition decisions.
  • Review and approve appropriate Corrective and Preventive Actions (CAPAs).
  • Escalate significant quality, compliance, or GMP issues and support local and global escalation activities where patient supply may be impacted.
  • Participate in hazard assessments and Quality Risk Management activities.
  • Coordinate, review, and deliver GMP training activities related to investigations, qualifications, and non-conformance management.
  • Support quality culture initiatives across manufacturing and laboratory operations, including GEMBA activities.
  • Review and approve document changes and change controls.
  • Lead or participate in local and global quality and capacity projects.
  • Enhance process monitoring and quality monitoring approaches.
  • Act as a Quality Subject Matter Expert (SME) during inspection preparation activities and support FDA, EMA, and other regulatory inspections.
  • Support Annual Product Reviews (APR), inspection readiness reports, and related compliance activities.
  • Partner with site colleagues to ensure changes to manufacturing processes, equipment, facilities, and systems are implemented in a controlled and compliant manner.
  • Participate in a rotating 24/7 on-call schedule as the QA representative for quality-related issues.
  • Represent Quality in Advanced Therapies projects, support identification and mitigation of compliance risks, review and approve study protocols and reports, and participate in Quality Risk Management and root cause investigation sessions.
  • Work closely with Operations, Quality Control, Warehouse, Manufacturing Asset Management (MAM), Manufacturing Science & Technology (MSAT), and other business partners to provide independent review and pragmatic quality guidance.
  • Support regulatory inspections and audits as part of normal responsibilities.
Desired Qualifications
  • Experience with methodologies such as Process Excellence, Co-Think, Kepner-Tregoe, or similar approaches.
  • Preferred skills include business alignment, business behavior, coaching, compliance management, continuous improvement, data analysis, detail orientation, goal attainment, human-centered design, internal controls, issue escalation, problem solving, process orientation, Quality Control (QC), Quality Management Systems (QMS), and quality standards.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.

CNBC
Oct 13th, 2026
J&J beats estimates and lifts forecast to $101.2B, but Middle East conflict hurts device sales

Johnson & Johnson (J&J) beat earnings estimates, but the Middle East conflict hurt its medical-device sales in the region. Chief financial officer Joe Wolk said Gulf states such as Kuwait, the UAE, and Saudi Arabia are shifting budgets towards defence. The conflict has not yet raised J&J's costs. Tremfya sales rose 68% to $2.4 billion, beating estimates of about $2.19 billion. Stelara sales, which face generic competition, fell 54% to $716 million, above expectations of $591 million. Darzalex sales rose about 16% to $4.24 billion, short of the $4.4 billion expected. J&J raised its full-year sales forecast to about $101.2 billion at the midpoint, from $101.1 billion. Its adjusted earnings midpoint rose to $11.10 per share from $11.04. Shares closed at $263.73 on Monday, up 27% this year.

Yahoo Finance
Oct 11th, 2026
J&J reports Q3 results on October 13 as $622.84B giant eyes $2.82 EPS

Johnson & Johnson will report third-quarter results on October 13, before the market opens. Analysts expect earnings per share (EPS) to edge up to $2.82, and the company has beaten EPS estimates in each of the past four quarters. The healthcare group, valued at $622.84 billion, has seen its stock rise 36.8% over 52 weeks. Shares are down 8.1% from their September 2 high of $281.07. In the second quarter, sales rose 6.6% to $25.31 billion, and adjusted EPS climbed 4.7% to $2.90. J&J raised its 2026 adjusted EPS estimate from $11.55 to $11.68. Of 25 analysts, 14 rate the stock "Strong Buy." The consensus price target of $282.60 implies 9.3% upside.